The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials.
Study Goal
The researchers aimed to assess the efficacy of bright light therapy (BLT) in treating seasonal affective disorder (SAD) in adults by comparing it to dim light or placebo.
Results Summary
BLT was found to be superior to placebo, with a standardized mean difference of -0.37 for depression ratings and a risk ratio of 1.42 for treatment response, though the studies showed moderate heterogeneity and risk of bias.
Population
Adults with seasonal affective disorder (SAD).
Effective Dosage
Bright light therapy (≥1,000 lx) via light box or light visor.
Duration
Not specified in the abstract.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Bright light therapy (BLT) | decrease | depression ratings | adults with seasonal affective disorder (SAD) | standardized mean difference of -0.37 (95% CI: -0.63 to -0.12) | was superior over placebo | #1 |
Bright light therapy (BLT) | increase | response to active treatment | adults with seasonal affective disorder (SAD) | risk ratio of 1.42 (95% CI: 1.08-1.85) | was superior over placebo | #2 |
Bright light therapy (BLT) | neutral | SAD | adults with seasonal affective disorder (SAD) | - | can be regarded as an effective treatment | #3 |
BACKGROUND: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. METHOD: We performed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT (≥1,000 lx, light box or light visor) against dim light (≤400 lx) or sham/low-density negative ion generators as placebo. Only first-period data were used from crossover trials. The primary outcome was the post-treatment depression score measured by validated scales, and the secondary outcome was the rate of response to treatment. RESULTS: A total of 19 studies finally met our predefined inclusion criteria. BLT was superior over placebo with a standardized mean difference of -0.37 (95% CI: -0.63 to -0.12) for depression ratings (18 studies, 610 patients) and a risk ratio of 1.42 (95% CI: 1.08-1.85) for response to active treatment (16 studies, 559 patients). We found no evidence for a publication bias, but moderate heterogeneity of the studies and a moderate-to-high risk of bias. CONCLUSIONS: BLT can be regarded as an effective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small-to-medium sample sizes, necessitating larger high-quality clinical trials.